120 related articles for article (PubMed ID: 34588149)
1. Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.
Gasparetto C; Jagannath S; Rifkin RM; Durie BGM; Narang M; Terebelo HR; Toomey K; Hardin JW; Wagner L; Ailawadhi S; Omel JL; Srinivasan S; Dhalla M; Catamero D; Kitali A; Agarwal A; Abonour R;
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):149-157. PubMed ID: 34588149
[TBL] [Abstract][Full Text] [Related]
2. Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.
Ailawadhi S; Jagannath S; Lee HC; Narang M; Rifkin RM; Terebelo HR; Durie BGM; Toomey K; Hardin JW; Gasparetto CJ; Wagner L; Omel JL; He M; Yue L; Flick ED; Agarwal A; Abonour R;
Cancer; 2020 Oct; 126(19):4332-4340. PubMed ID: 32706404
[TBL] [Abstract][Full Text] [Related]
3. Development of a prognostic model for overall survival in multiple myeloma using the Connect
Terebelo HR; Abonour R; Gasparetto CJ; Toomey K; Durie BGM; Hardin JW; Jagannath S; Wagner L; Narang M; Flick ED; Srinivasan S; Yue L; Kitali A; Agarwal A; Rifkin RM;
Br J Haematol; 2019 Dec; 187(5):602-614. PubMed ID: 31382320
[TBL] [Abstract][Full Text] [Related]
4. Connect MM Registry as a national reference for United States multiple myeloma patients.
Ailawadhi S; Jagannath S; Narang M; Rifkin RM; Terebelo HR; Toomey K; Durie BGM; Hardin JW; Gasparetto CJ; Wagner L; Omel JL; Kumar V; Yue L; Kitali A; Agarwal A; Abonour R;
Cancer Med; 2020 Jan; 9(1):35-42. PubMed ID: 31701679
[TBL] [Abstract][Full Text] [Related]
5. Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data.
Kaur G; Mejia Saldarriaga M; Shah N; Catamero DD; Yue L; Ashai N; Goradia N; Heisler J; Xiao Z; Ghalib N; Aaron T; Cole D; Foreman R; Mantzaris I; Derman O; Bachier L; Sica RA; Kornblum N; Braunschweig I; Shastri A; Goel S; Verma A; Janakiram M
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e384-e397. PubMed ID: 33339770
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
Rifkin RM; Jagannath S; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Parikh K; Abouzaid S; Srinivasan S; Kitali A; Zafar F; Abonour R
Clin Ther; 2018 Jul; 40(7):1193-1202.e1. PubMed ID: 30007443
[TBL] [Abstract][Full Text] [Related]
7. Superior Survival in African American Patients Who Underwent Autologous Stem Cell Transplantation for Multiple Myeloma.
Sweiss K; Oh A; Calip GS; Rondelli D; Patel P
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e506-e511. PubMed ID: 31231013
[TBL] [Abstract][Full Text] [Related]
8. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
Jagannath S; Abonour R; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Agarwal A; Srinivasan S; Kitali A; Flick ED; Sturniolo M; Rifkin RM
Blood Adv; 2018 Jul; 2(13):1608-1615. PubMed ID: 29986853
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.
Shah JJ; Abonour R; Gasparetto C; Hardin JW; Toomey K; Narang M; Srinivasan S; Kitali A; Zafar F; Flick ED; Rifkin RM
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):575-583.e2. PubMed ID: 28886839
[TBL] [Abstract][Full Text] [Related]
10. Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting.
Vargas-Serafin C; Acosta-Medina AA; Ordonez-Gonzalez I; Martínez-Baños D; Bourlon C
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):182-187. PubMed ID: 33414064
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
[TBL] [Abstract][Full Text] [Related]
12. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.
Medhekar R; Ran T; Fu AZ; Patel S; Kaila S
BMC Cancer; 2022 Aug; 22(1):901. PubMed ID: 35982416
[TBL] [Abstract][Full Text] [Related]
13. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
[TBL] [Abstract][Full Text] [Related]
14. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma.
Verma PS; Howard RS; Weiss BM
Am J Hematol; 2008 May; 83(5):355-8. PubMed ID: 18186525
[TBL] [Abstract][Full Text] [Related]
15. Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
Ballas L; Ailawadhi S; Narang M; Gasparetto CJ; Lee HC; Hardin JW; Durie BGM; Toomey K; Omel J; Wagner LI; Abonour R; Terebelo HR; Joshi P; Yu E; Liu L; Rifkin RM; Jagannath S
Pract Radiat Oncol; 2024; 14(2):e141-e149. PubMed ID: 37984714
[TBL] [Abstract][Full Text] [Related]
16. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
17. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis.
Ailawadhi S; Advani P; Yang D; Ghosh R; Swaika A; Roy V; Foran J; Colon-Otero G; Chanan-Khan A
Cancer; 2016 Feb; 122(4):618-25. PubMed ID: 26565660
[TBL] [Abstract][Full Text] [Related]
18. Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.
Jagannath S; Rifkin RM; Gasparetto CJ; Toomey K; Durie BGM; Hardin JW; Terebelo HR; Wagner L; Narang M; Ailawadhi S; Omel JL; Srinivasan S; He M; Ung B; Kitali A; Flick ED; Agarwal A; Abonour R;
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):272-276. PubMed ID: 32144027
[No Abstract] [Full Text] [Related]
19. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Cavo M; San-Miguel J; Usmani SZ; Weisel K; Dimopoulos MA; Avet-Loiseau H; Paiva B; Bahlis NJ; Plesner T; Hungria V; Moreau P; Mateos MV; Perrot A; Iida S; Facon T; Kumar S; van de Donk NWCJ; Sonneveld P; Spencer A; Krevvata M; Heuck C; Wang J; Ukropec J; Kobos R; Sun S; Qi M; Munshi N
Blood; 2022 Feb; 139(6):835-844. PubMed ID: 34289038
[TBL] [Abstract][Full Text] [Related]
20. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
